AFB Releases Phase 2 Study of Barriers to Digital Inclusion
May 10, 2024 12:39 ET
|
American Foundation for the Blind
AFB Researchers uncover further barriers to digital inclusion for blind and low vision.
Merus gibt Finanzergebnisse für das erste Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf
May 10, 2024 12:36 ET
|
Merus N.V.
Petosemtamab in Kombination mit Pembrolizumab bei 1L (Erstlinientherapie) HNSCC – erste vorläufige klinische Daten auf der ASCO-Jahrestagung 2024; Vorbereitung einer möglichen Phase-III-StudieZeno-BLA...
Merus annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités
May 10, 2024 12:36 ET
|
Merus N.V.
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées lors du congrès annuel de l’ASCO 2024 ;...
Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights – AVXL
May 10, 2024 12:36 ET
|
Levi & Korsinsky, LLP
NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action...
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
May 10, 2024 09:35 ET
|
Immix Biopharma, Inc.
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to...
Vaccines Market is Expected to Reach $94.9 billion | MarketsandMarkets™
May 10, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 10, 2024 (GLOBE NEWSWIRE) -- Vaccines market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0%...
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024 08:26 ET
|
iTeos Therapeutics Inc.
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
May 10, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies...
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
May 10, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...
Next Hydrogen Reports Q1 2024 Financial Results
May 10, 2024 07:00 ET
|
Next Hydrogen Corporation
MISSISSAUGA, Ontario, May 10, 2024 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased...